Short communication · 26 Nov 2021
Conference abstractPublished 21 Oct 2013
Saudi FDA reporting system - NCMDR
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Since 2008 medical devices sector within Saudi Food and Drug Authority lunch first of its kind in the region an on line reporting system works as an organization managing a database devoted to receive adverse event reports about any medical devices malfunction from hospital and healthcare facilities all around Kingdom of Saudi Arabia, studying them and working together with manufacturers, authorized representatives, importers and distributors to take the appropriate action and assuring the safe performance of those medical devices placed on KSA market or put in service . The goals behind establishing this national center are to: ? Improve protection of the health and safety of patients, users and others. ? Disseminate relevant device related information which may reduce the likelihood of, or prevent repetition of adverse events, or alleviate consequences of such repetition. ? Encourage collaboration between manufacturers and healthcare providers to identify and investigate adverse events associated with medical devices and take appropriate action to execute a key aspect of SFDA?s post market activities ?surveillance?. NCMDR has full leverage membership of GHTF NCAR currently IMDRF which are among USA, Canada, EU, Australia, Japan, China and Brazil. Also NCMDR has membership of AHWP SADA which includes in its membership more than 22 member economies. This paper will address the importance of NCMDR, who makes the recall / FSN, what should be reported, some snap shot from the system and some statistics.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 22 Aug 2016
Adverse renal effects of novel molecular oncologic targeted therapies: A review of the FDA adverse event reporting system (FAERS)
Research article · 2015
Assessing Risks of Impaired Healing and Osteomyelitis Associated with Bisphosphonates Using FDA Adverse Event Reporting System (FAERS)
Research article · 2013
Assessing Pancreatic Cancer Risk Associated with Dipeptidyl Peptidase 4 Inhibitors: Data Mining of FDA Adverse Event Reporting System (FAERS)
Conference abstract · 21 Oct 2013
Regulatory submissions for blood products at Saudi FDA
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 13 Feb 2026
Regulatory Scenario of Pharmaceuticals during COVID-19 Pandemic in India
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Essam M. Al Mohandis”

